ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1567504
This article is part of the Research TopicNovel anti-cancer drugs combination radio-immunotherapy strategy: new frontiers in cancer immunotherapyView all articles
Combined Stereotactic Radiation Therapy and Immunotherapy for Metastatic Uveal Melanoma
Provisionally accepted
Valeria V. Nazarova1,2
Kristina V. Orlova1
Zakhra R. Magomedova1
Denis S. Romanov3
Roman V. Moskalenko4
Andrey A. Yarovoy5Vera A. Yarovaya6Oxana P. Trofimova1
Irina Zh. Shubina1*Lev V. Demidov1- 1Russian Cancer Research Center NN Blokhin, Moscow, Moscow Oblast, Russia
- 2Pirogov Russian National Research Medical University, Moscow, Moscow Oblast, Russia
- 3Senter for Innovative Medical Technologies, Moscow, Russia
- 4LLC "OncoStop", Moscow, Russia
- 5S.N.Fedorov MNTK "Eye Microsurgery", Moscow, Russia
- 6S.N.Fedorov MNTK 'Eye Microsurgery', Moscow, Moscow Oblast, Russia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Aim: Uveal melanoma (UM) is a rare primary intraocular malignant tumor with an extremely poor prognosis. Our study evaluated the feasibility to improve metastatic UM treatment outcomes with a combined approach of immunotherapy and radiation therapy. Methods: The retrospective study enrolled 24 patients with metastatic uveal melanoma who had combined treatment with stereotactic radiation therapy (RT) and immune checkpoint inhibitor therapy. 35% of patients received combination immunotherapy, and the others received monoimmunotherapy with anti-PD-1 drugs. All patients underwent stereotactic RT for metastases in the liver (75% patients), bones (8%), soft tissues (8%), brain (4%), and lungs (4%). Results: Overall response rate (ORR) was 39.1%. Complete response (CR) was achieved in 8.7% patients and partial response (PR)in 30.4% patients, median progression free survival (PFS) was 11.6 months [95% confidence interval (CI), 5.4-14.4], and median overall survival (OS) was 27.6 months [95% CI, 16.9 -49.1].The study has demonstrated a safe combination of stereotactic radiation therapy and immune checkpoint inhibitor immunotherapy in patients with metastatic uveal melanoma. The combination shows a potential treatment option for this patient cohort since no other effective therapies are available at present.
Keywords: Metastatic uveal melanoma, Immunotherapy, stereotactic radiotherapy, overall survival, response rate
Received: 27 Jan 2025; Accepted: 14 Apr 2025.
Copyright: © 2025 Nazarova, Orlova, Magomedova, Romanov, Moskalenko, Yarovoy, Yarovaya, Trofimova, Shubina and Demidov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Irina Zh. Shubina, Russian Cancer Research Center NN Blokhin, Moscow, 115478, Moscow Oblast, Russia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.